Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Ramucirumab Action Pathway
Homo sapiens
Drug Action Pathway
Ramucirumab serves as an antineoplastic agent and direct antagonist of VEGFR2 (vascular endothelial growth factor receptor 2), counteracting the binding of natural VEGF ligands secreted by solid tumors. This action inhibits angiogenesis and the enhancement of tumor blood supply, pivotal processes for cancer progression. It is a human monoclonal antibody (IgG1) designed against VEGFR2, a transmembrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab disrupts the binding of ligands (VEGF-A, VEGF-C, and VEGF-D), thereby impeding receptor phosphorylation and downstream cellular responses like proliferation, permeability, and migration of endothelial cells. Since VEGFR stimulation plays a crucial role in angiogenesis and cancer progression, ramucirumab's targeted interference is highly significant. Notably, it binds to a specific epitope on the extracellular domain of VEGFR-2, blocking all VEGF ligands from binding. Ramucirumab finds application in the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, metastatic non-small cell lung cancer with specific genomic mutations, metastatic colorectal cancer, and hepatocellular carcinoma, often in combination with other therapies.
References
Ramucirumab Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Goodkin R, Zaias B, Michelsen WJ: Arteriovenous malformation and glioma: coexistent or sequential? Case report. J Neurosurg. 1990 May;72(5):798-805
Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R: FDA Approval Summary: Ramucirumab for Gastric Cancer. Clin Cancer Res. 2015 Aug 1;21(15):3372-6. doi: 10.1158/1078-0432.CCR-15-0600. Epub 2015 Jun 5
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings